Fetal cardiofibroelastosis - a consequence of anti-Ro maternal transfer during pregnancy. Case report and review of the literature

Ana Duminica Turcu², Nicolae Gica¹², Radu Botezatu¹², Gheorghe Peltecu¹², Anca Maria Panaitescu¹²

¹“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
²Filantropia Clinical Hospital, Bucharest, Romania

ABSTRACT
With scarcely any reports published on the association of fetal endocardial fibroelastosis and Ro antibodies maternal transfer during pregnancy, this subject continues to raise concern among health care providers around the world, especially when neonatal lupus syndrome is taken into consideration as the main diagnosis. Fetuses with congenital atrioventricular block have a risk of intrauterine fetal demise and the concern comes from a variety of factors that show significant association between the presence of maternal antibodies to SS-A/Ro during pregnancy and their children serum level of these antibodies. Nevertheless, fetal endocardial fibroelastosis plays an important role in altering ventricular diastolic function and ventricular development in children and neonates.

Methods. Medical literature was searched on PubMed and Medline using key words such as fetal endocardial fibroelastosis, anti-Ro antibodies in pregnancy and neonatal lupus syndrome and over 200 articles were taken into consideration, with 17 of them included in the final review. The clinical case included in this paper was referred to the Department of Maternal Fetal Medicine, Filantropia Clinical Hospital in Bucharest, during the second pregnancy after a first pregnancy that resulted in stillbirth with congenital heart block and fibroelastosis as a result of the maternal diagnosis of Sjogren’s syndrome with transplacental transfer of SS-A/Ro antibodies.

Keywords: fetal endocardial fibroelastosis, anti-Ro antibodies, pregnancy, neonatal lupus syndrome

INTRODUCTION
It was suggested that antibodies to SS-A/Ro occupy a crucial role in the diagnosis of neonatal lupus syndrome, as congenital heart block (CHB) frequently coexisting with cutaneous lupus are the main clinical components illustrating this syndrome [1]. According to Reed et al., anti Ro/La antibodies that are discovered in the serum of the mother could also be found in their neonates serum, a notion promoted by the study of 12 children diagnosed with congenital heart block, 16,67% of them associating cutaneous lupus lesions [1]. The same results were stated earlier, in 1983, during a study conducted by Scott et al., in which it was described that antibodies to SS-A/Ro are vertically transmitted and they are likely to be associated with congenital complete heart block [2].

CASE REPORT
A 30-year-old female G2P2, with a first pregnancy that ended up in stillbirth at 23 weeks of gestation as a result of transplacental passage of maternal anti-Ro antibodies that caused congenital heart block with fetal hydrops and heart failure, presented in our clinic for antenatal care during her second pregnancy. The patient was diagnosed with Sjogren’s syndrome that associated anti-Ro antibodies during her first pregnancy. After the second pregnancy confirmation at 6 weeks gestation, prophylactic Hydroxychloroquine was proposed.

Examination
First trimester ultrasound assessment was within normal range. The patient was constantly moni-
tored and at 22 weeks of gestation, the ultrasound assessment identified no fetal structural anomalies, except recurrent intermittent second- and third-degree atrioventricular block with intermittent fetal bradycardia with no signs of cardiac insufficiency or fibroelastosis.

Management

Dexamethasone therapy was proposed at a daily dose of 4 mg, given to the patient orally, daily, and the treatment was continued throughout the rest of pregnancy. The patient gave birth via cesarean secton after premature rupture of membranes at 36 weeks of pregnancy. Birth weight was 2.6kg and Apgar score at 5 minutes was 9. Neonatal anti-Ro antibodies were positive, the neonatal electrocardiogram showed a third-degree atrioventricular block with ventricular rate of 80 beats per minute and neonatal echocardiography showed no cardiac anomalies, except mild pericardial effusion. Neonatal treatment included steroids, immunoglobulin, isoprenaline and diuretic and nearly half a year later, no ventricular dysfunction was present.

DISCUSSION

Definition of endocardial fibroelastosis

According to Zhang et al, endocardial fibroelastosis (EFE) is defined as extreme expansion of fibrous and elastic tissue that leads to endocardium widening, a process that mainly affects infants and children, altering ventricular diastolic function and ventricular development [3]. The etiology has been described as multifactorial, such as genetic X-linked recessive, infectious, viral, but also autoimmune with the association of anti-Ro and anti-La antibodies, although a large number of the cases remains idiopathic [4]. As endocardial fibroelastosis is still considered uncommon, the incidence and prevalence are not well described in the current literature. Lipshultz et al. published a scientific statement from the American Heart Association in 2019 in which the incidence of pediatric cardiomyopathy is established as 1 per 100 000 children, thus including endocardial fibroelastosis [5]. The main pathophysiological factor is accumulation of acellular fibrocartilaginous components in the endocardium, especially in the subendothelial lamina, to such a degree that macroscopically, the normal transparent endocardium becomes bright white, frequently associated with myocardial increased thickness and valvular impairment [4,5]. The endocardium consists of five layers and during the process of cardio-fibroelastosis all the layers are impaired, with addition of elastin and collagen fibers, a process that was studied by Fishbein et al. by staining elastic fibers with silver tetraphenyl-porphin sulfonate [6]. Although the clinical presentation of cardio-fibroelastosis is complex, especially during intrauterine life, Seki et al. investigated 52 pediatric heart transplant cases and recommended pathological criteria for the diagnosis of cardio-fibroelastosis as they are seen in Table 1 [7].

| TABLE 1. Criteria of pathological diagnosis of cardio-fibroelastosis proposed by Seki et al. [7] |
|-----------------|-------------------------------------------------|-------------------------------------------------|
|                  | Lack of auxiliary inherited malformations       | Lack of concealed vascular, metabolic, or inflammatory diseases |
|                  | Spherical or dilated left ventricle (LV)        | Disseminated expansion of left ventricle endocardium |
|                  | Left ventricle papillary muscles reallocated ascensive and close to the left atrium | Widened free edges of mitral valve leaflets |
|                  | Cluster of elastic fibers in the endocardium    |                                                                   |

The role of SS-A/Ro antibodies

When systemic autoimmune diseases are diagnosed, among the most prevalent antibodies that are found in these syndromes, are the antibodies against ENA (extractable nuclear antigens), the most acknowledged of them being Anti-Ro/SSA and anti-La/SSB antibodies. Besides being one of the most important criteria of diagnosis of Sjögren’s syndrome, according to Wenzel et al., the anti-Ro/SSA and anti-La/SSB antibodies are also found in a high percentage in the serum of these patients [8]. First described in 1961 by Anderson et al., anti-Ro/SSA and anti-La/SSB antibodies precipitate when they are adjacent to antigens which are found in the salivary and lacrimal glands of patients with Sjögren’s syndrome [9]. In a paper published by Schulte-Pelkum et al. in 2009, it was stated that although anti-Ro/SSA antibodies are associated with numerous systemic autoimmune diseases (Table 2), Ro60 (SS-A) and Ro52 embody two different autoantibody structures [10].

| TABLE 2. Systemic autoimmune diseases that associate anti-Ro/SSA antibodies proposed by Schulte-Pelkum and al in 2009 [10] |
|-------------------------------------------------|-------------------------------------------------|
| Dermatomyositis                                  | Mixed connective tissue disease |
| Polymyositis                                     | Rheumatoid arthritis |
| Sjögren’s syndrome                               | Systemic sclerosis |
| Systemic lupus erythematosus                     |                                                                   |

SS-A/Ro antibodies and congenital heart block

Ho et al. studied eight patients with congenital heart block, 87.5% of them associating SS-A/Ro ma-
ternal antibodies [11]. The pathogenesis of congeni-
tal heart block associated with SS-A/Ro maternal
antibodies consists of abnormal signal transmission
of the atrio-ventricular node as result of the inflam-
matory process induced by vertical transmission of
SS-A/Ro maternal antibodies [11]. Nevertheless, in
the PR Interval and Dexamethasone Evaluation
(PRIDE) prospective study that was published in
2008, 127 patients with anti-SSA/Ro antibodies were
evaluated emphasizing the association between congenital heart block in offspring’s and maternal
antibodies to SSA/Ro-SSB/La [12]. As congenital
heart block was better identified between 18 and 24
weeks of gestation, intrauterine treatment could be
established, with options such as prednisone, dexamethasone, and/or plasmapheresis and weekly
heart ultrasound follow-up in order to assess early
manifestations of cardiac deterioration such as mi-
tral or tricuspid regurgitation, left ventricular dil-
tation, inadequate contraction, pericardial effusion
or hydrops fetalis [12]. According to Bordachar,
pregnant women with anti-Ro/Sjögren’s syndrome
antigen A (SSA) and anti-La/Sjögren’s syndrome
antigen B (SSB) have a risk of 2–5% to associate fetal
cardiac heart block during the first pregnancy, and
12–25% if previous pregnancies associated fetal car-
diac heart block [13]. Data from a study that enrolled
33 pregnant women showed that the usage of hy-
droxycloroquine (HCQ) could contribute to the
prevention of congenital heart block, its mechanism
consists of inhibiting toll-like receptor signaling that
has a role in the immune response [14]. Other treat-
ment options include dexamethasone, a fluorinated
steroid that diminishes maternal antibody levels,
administered orally or intravenously, on a daily ba-
sis, until delivery [15]. Nonetheless, a multicenter,
prospective, open-label clinical trial published in
2010 considered intravenous immunoglobulin
(IVIG) as a potential therapy for cardiac heart block,
400 mg/kg every 3 weeks from 12–24 weeks of gesta-
tion having the ability to impede recurrence of car-
diac heart block [16], while Ruffatti et al. noted in a
2011 report that a combined therapy that included
plasmapheresis and intravenous immunoglobulin
with a corticosteroid could convert second degree
atrioventricular block to first degree atrioventricu-
lar block [17].

CONCLUSIONS

The existence of anti-SSA/Ro or anti-SSB/La anti-
odies during pregnancy imply a high risk of fetal
cardiac impairment, while the development of fetal
endocardial fibroelastosis plays an important role
in altering ventricular diastolic function and ven-
tricular disfunction progress in children and neo-
mates. Pregnant women that associate a previous
pregnancy affected by fetal cardiac heart block
should be offered a particular antenatal care that
includes fetal echocardiography monitoring from
16–18 to 28 weeks of gestation every two weeks.
Proper treatment options should be considered
from the moment of pregnancy confirmation until
delivery. Extensive attention must be given to the
intrapartum monitoring during labor, as this im-
plies a difficult monitoring of atrial and ventricular
fetal heart rate. Nonetheless, there are multiple an-
tenatal treatment options such as hydroxychloro-
quine, dexamethasone, plasmapheresis or intrave-
nous immunoglobulin.

Conflict of interest: none declared
Financial support: none declared

REFERENCES

1. Reed BR, Lee LA, Harmon C, Wolfe R, Wiggins J, Peebles
C, Weston WL. Autoantibodies to SS-A/Ro in infants with
congenital heart block. J Pediatr. 1983 Dec;103(6):889-91.
2. Scott JS, Maddison PJ, Taylor PV, Esscher E, Scott O, Skinner RP.
Connective-tissue disease, antibodies to ribonucleoprotein, and
congenital heart block. N Engl J Med. 1983 Jul 28;309(4):209-12.
3. Zhang H, Huang X, Liu K, Tang J, He L, Pu W et al. Fibroblasts
in an endocardial fibroelastosis disease model mainly originate
from mesenchymal derivatives of epicardium. Cell Res. 2017
Sep;27(9):1157-1177.
4. Lurie PR. Changing concepts of endocardial fibroelastosis. Cardiol Young. 2010 Apr;20(2):115-23.
5. Lipshultz SE, Law YM, Lawante-Korang A, Austin ED, Dipchand
Al, Everitt MD et al. Cardiomyopathy in Children: Classification
and Diagnosis: A Scientific Statement From the American Heart
Association. Circulation. 2019 Jul 2;140(1):e9-e68.
6. Fishbein MC, Ferrans VJ, Roberts WC. Histologic and ultrastruc-
tural features of primary and secondary endocardial fibroelasto-
sis. Arch Pathol Lab Med. 1977 Jan;101(1):49-54.
7. Seki A, Patel S, Ashraf S, Perens G, Fishbein MC. Primary endocar-
dial fibroelastosis: an underappreciated cause of cardiomyopa-
thy in children. Cardiovasc Pathol. 2013 Sep-Oct;22(5):345-50.
8. Wenzel J, Gerdsen R, Uerlich M, Bauer R, Bieber T, Boehm
I. Antibodies targeting extractable nuclear antigens: histori-
cal development and current knowledge. Br J Dermatol. 2001
Dec;145(6):859-67.
9. Anderson JR, Gray KG, Beck JS, Kinnear WF. Precipitating autoanti-
bodies in Sjögren’s disease. Lancet. 1961 Aug 26;2(7200):456-60.
10. Schulte-Pelkum J, Fritzler M, Mahler M. Latest update on the Ro/
SS-A autoantibody system. Autoimmun Rev. 2009 Jun;8(7):632-7.
11. Ho SY, Esscher E, Anderson RH, Michaëlsson M. Anatomy of con-
genital complete heart block and relation to maternal anti-Ro
antibodies. Am J Cardiol. 1986 Aug 1;58(3):291-4.
12. Friedman DM, Kim MY, Copel JA, Davis C, Phoon CK, Glickstein
JS, Buyon JP. PRIDE Investigators. Utility of cardiac monitoring
in fetuses at risk for congenital heart block: the PR Interval
and Dexamethasone Evaluation (PRIDE) prospective study.
Circulation. 2008 Jan 29;117(4):485-93.
13. Bordachar P, Zachary W, Ploux S, Labrousse L, Haissaguerre M, Thambo JB. Pathophysiology, clinical course, and management of congenital complete atrioventricular block. *Heart Rhythm*. 2013 May;10(5):760-6.

14. Tunks RD, Clowse ME, Miller SG, Brancazio LR, Barker PC. Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents. *Am J Obstet Gynecol.* 2013 Jan;208(1):64.e1-7.

15. Hunter LE, Simpson JM. Atrioventricular block during fetal life. *J Saudi Heart Assoc.* 2015 Jul;27(3):164-78.

16. Friedman DM, Llanos C, Izmirly PM, Brock B, Byron J, Copel J et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. *Arthritis Rheum.* 2010 Apr;62(4):1138-46.

17. Ruffatti A, Milanesi O, Chiandetti L, Cerutti A, Gervasi MT, De Silvestro G et al. A combination therapy to treat second-degree anti-Ro/La-related congenital heart block: a strategy to avoid stable third-degree heart block? *Lupus.* 2012 May;21(6):666-71.